Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CLDN18.2 Positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Not Yet RecruitingNCT07716449
What this trial is testing

QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Qilu Pharmaceutical Co., Ltd. 560
Testing effectiveness (Phase 2)Looking for participantsNCT06587425
What this trial is testing

The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Shanghai Zhongshan Hospital 50
Testing effectiveness (Phase 2)Study completedNCT05161390
What this trial is testing

Study of LM-302 in Patients With Advance Solid Tumors

Who this might be right for
Advanced Solid Tumor
LaNova Medicines Zhejiang Co., Ltd. 153
Testing effectiveness (Phase 2)Study completedNCT05190575
What this trial is testing

TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

Who this might be right for
Biliary Tract Neoplasms
Shanghai Zhongshan Hospital 8
Testing effectiveness (Phase 2)Looking for participantsNCT07460375
What this trial is testing

Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
LigaChem Biosciences, Inc. 191
Large-scale testing (Phase 3)Not Yet RecruitingNCT07795346
What this trial is testing

ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Antengene Biologics Limited 380
Early research (Phase 1)UnknownNCT05837299
What this trial is testing

IMC008 for Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Changhai Hospital 18
Testing effectiveness (Phase 2)Looking for participantsNCT05205850
What this trial is testing

RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Who this might be right for
Advanced Solid Tumor
RemeGen Co., Ltd. 135
Not applicableUnknownNCT05952375
What this trial is testing

Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial

Who this might be right for
Gastric Cancer
The Affiliated Hospital of Qingdao University 9
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07704866
What this trial is testing

A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors

Who this might be right for
Claudin 18.2Solid Tumor Malignancies
FutureGen Biopharmaceutical (Beijing) Co., Ltd 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06881017
What this trial is testing

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Who this might be right for
Gastric CancerHER2 + Gastric CancerCLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction+1 more
China Medical University, China 140
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07415525
What this trial is testing

IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer

Who this might be right for
Pancreatic CancerBorderline Resectable Pancreatic Adenocarcinoma
Zhejiang University 40
Early research (Phase 1)Looking for participantsNCT05857332
What this trial is testing

SG1906 for CLDN18.2-Positive Solid Tumors

Who this might be right for
Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd. 60
Testing effectiveness (Phase 2)Looking for participantsNCT07450976
What this trial is testing

SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 151
Testing effectiveness (Phase 2)Ended earlyNCT04683939
What this trial is testing

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors

Who this might be right for
Solid TumorGastric CancerGastroesophageal Junction Adenocarcinoma+5 more
BioNTech SE 13
Very early researchNot Yet RecruitingNCT07394205
What this trial is testing

Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer

Who this might be right for
Advanced Gastric and Pancreatic Cancer
First Affiliated Hospital of Wenzhou Medical University 18
Early research (Phase 1)UnknownNCT05472857
What this trial is testing

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Who this might be right for
Gastric CancerPancreatic CancerAdvanced Ovarian Carcinoma+1 more
Suzhou Immunofoco Biotechnology Co., Ltd 30
Very early researchLooking for participantsNCT07680257
What this trial is testing

An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors

Who this might be right for
CLDN18.2 Positive Solid Tumors
Celest Therapeutics (Shanghai) Co., Ltd. 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT05862324
What this trial is testing

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

Who this might be right for
Metastatic Solid Tumor
Triumvira Immunologics, Inc. 113
Not applicableAvailableNCT06048081
What this trial is testing

Early Access Program for Zolbetuximab

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma CancerLocally Advanced Unresectable Gastric Adenocarcinoma CancerMetastatic Gastric Adenocarcinoma Cancer+1 more
Astellas Pharma Global Development, Inc.
Next Page